4D Molecular provides pipeline progress, near-term milestones

4D Molecular Therapeutics announced clinical pipeline progress, updates to near-term milestones and organizational updates. Large Market Ophthalmology Portfolio Recent Updates and Expected Upcoming Milestones: 4D-150 for Wet AMD: Phase 2 PRISM Clinical Trial – Randomized Dose Expansion arm in advanced high treatment need patients: Initial interim 24 week landmark data to be presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference. Population Extension arm n broad population: Enrollment update expected in Q1 2024; Initial interim 24 week landmark data analysis expected in H2 2024. Update on Phase 3 trial plans expected in February 2024 along with the interim randomized Phase 2 PRISM trial data. 4D-150 for DME: – Phase 2 SPECTRA Clinical Trial: Part 1 – Dose Confirmation Stage: Completed enrollment in Q4 2023; Initial interim 24 week landmark data expected in H2 2024. 4D-175 for Geographic Atrophy: IND filing expected in Q2 2024; Phase 1 initiation expected in H2 2024. Pulmonology Portfolio Expected Upcoming Milestones: 4D-710 for CF Lung Disease: Update on FDA feedback on development plan for monotherapy and approved CF modulator combination regimens expected in Q1 2024; Interim data update from Phase 1/2 AEROW clinical trial expected in mid-2024. 4D-725 for A1AT Deficiency Lung Disease: Program update and initiation of IND-enabling studies expected in 2024. Cardiology Franchise Expected Upcoming Milestones: 4D-310 for Fabry Disease Cardiomyopathy: Interim data update including cardiac functional, imaging, quality-of-life and cardiac biopsy data for all 6 patients dosed to be presented in the late-breaking session at the WORLDSymposium 2024 in San Diego, California on Friday, February 9. FDA submission of data from the non-human primate study evaluating the safety and biodistribution of intravenous 4D-310 with the rituximab/sirolimus immunosuppressive regimen compared to the prior prednisone regimen expected in Q2 2024. Rare Inherited Retinal Disorders Portfolio Expected Upcoming Milestones – 4D-110 for Choroideremia and 4D-125 for X-Linked Retinitis Pigmentosa: The safety and tolerability profiles for both product candidates remain unchanged from prior data releases. All enrolled patients are expected to reach 24 months of follow-up in 2024, and we plan to assess the magnitude and durability of key imaging and functional endpoint changes in evaluable patients. We expect to provide program updates in 2024.